Engineered bacteria and engineered probiotics for intestinal disease therapy: bibliometric and knowledge mapping analysis
Scientific output on engineered bacteria and probiotics for intestinal disease grew continuously from 2015 to 2025, with a thematic shift from conventional anti-inflammatory effects toward antitumor therapy and self-regulated genetic circuits — but this study establishes no clinical outcomes in patients.
| Population | Scientific literature on engineered bacteria and probiotics applied to intestinal diseases (2015–2026), without restriction by species or specific condition |
|---|---|
| Intervention | Bibliometric and knowledge mapping analysis of 499 publications indexed in Web of Science and Scopus |
| Comparator | Not applicable (descriptive study with no control group) |
| Outcome | Annual publication trends; Geographic distribution and scientific output leadership; Dominant research topics (keyword co-occurrence); Thematic shift identified by co-citation and timeline analysis; Emerging research fronts |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Annual publication trends | 109 publications in 2025; 64 in 2026 (partial year); in the CI reported | — | Very low | — | 499 studies |
| Geographic distribution and scientific output leadership | Asia 361/499 publications; China highest output; USA highest total link strength; in the effect size calculable | — | Very low | — | 499 studies |
| Dominant research topics (keyword co-occurrence) | Descriptive network analysis; in the quantitative effect size; IBD, gut microbiota, synthetic biology, colorectal cancer identified as hubs | — | Very low | — | 499 studies |
| Thematic shift identified by co-citation and timeline analysis | Qualitative shift from anti-inflammatory/barrier effects to chassis selection, self-regulated circuits, antitumor therapy; in the quantitative metric reported | — | Very low | — | 499 studies |
| Emerging research fronts | Keyword burst analysis identifies probiotic biomaterials, sustained-release delivery, engineered bacteria antitumor therapy as emerging; in the CI or effect size | — | Very low | — | 499 studies |
Context
Living engineered bacteria represent an emerging therapeutic frontier for intestinal diseases such as IBD and colorectal cancer. Mapping the field structure informs research priorities and regulatory gaps. This study maps published literature; it does not evaluate clinical efficacy or safety.
What the study showed
Publication volume increased markedly, reaching 109 articles in 2025; 64 records were retrieved for 2026 by the cutoff date. China led in publication volume; the United States showed the highest network link strength. Keyword analysis identified IBD, gut microbiota, probiotics, synthetic biology, intestinal barrier, drug delivery, colorectal cancer, and immunotherapy as central topics. Timeline analysis revealed a shift from conventional anti-inflammatory effects to bacterial chassis selection, self-regulated genetic circuits, and engineered bacteria-mediated antitumor therapy.
How it was done
Bibliometric review of 499 publications (2015–2026) retrieved from Web of Science Core Collection and Scopus, after publication type restriction, thematic relevance screening, and duplicate removal. Tools used: R, Python, VOSviewer, and CiteSpace for network analysis, co-citations, and keyword trends. Cutoff date was July 3, 2026; 2026 data represent a partial year.
Effect magnitude
No clinical effect size was calculated; the study is descriptive. Publication growth from 2015 to 2025 is documented but no growth rate with confidence interval is reported.
Risk of bias
No risk of bias tool (RoB 2, ROBINS-I, AMSTAR-2) was applied, as the study is not a systematic review of clinical trials. Inclusion of only two databases (WoS and Scopus) may have omitted relevant publications from other sources. The mixture of publication types limits corpus homogeneity. 2026 data are partial and subject to temporal cutoff publication bias.
What this study does NOT prove
This study does NOT prove efficacy, safety, or clinical superiority of any engineered probiotic or bacterium over existing treatments. Bibliometric trends do not constitute intervention evidence.
In clinical practice
This study provides no evidence for direct clinical decision-making. Clinicians may use the mapping to identify active research areas (antitumor therapy, genetic circuits, probiotic biomaterials) and assess which regulatory and clinical gaps remain unfilled. No therapeutic recommendation can be derived from this work.
Limitations
No risk of bias tool (RoB 2, ROBINS-I, AMSTAR-2) was applied, as the study is not a systematic review of clinical trials. Inclusion of only two databases (WoS and Scopus) may have omitted relevant publications from other sources. The mixture of publication types limits corpus homogeneity. 2026 data are partial and subject to temporal cutoff publication bias.
What is still missing
Systematic reviews and meta-analyses of clinical trials with engineered bacteria on primary outcomes (IBD remission, colorectal cancer survival) are needed. Human safety studies and long-term regulatory evaluation are absent from the mapped literature.
Technical appendix
Version history
- 1.0 · 2026-10-11 — Auto-generated under Evidence Standard v1.0